PubMed Health⌕ Search

Biomedical subjects

R A Sabadyshin

Publications and source records attributed to R A Sabadyshin.

10 recordsLinked to original sources
PubMed1992

[The significance of the antioxidant properties of emoxipin in the combined treatment of patients with chronic heart failure].

It was found that emoxypin (40 mg daily) with nitrates of prolonged action and corinfar used in 87 patients with chronic cardiac insufficiency (CCI) reduces the concentration of primary and secondary products of lipid peroxidation to control levels which is not observed when only corinfar and nitrates of prolonged action were used. Simultaneous use of prazosin and emoxypin favoured balanced oxidant-antioxidant system of the body.

Adult↗
PubMed1991

[Effects of emoxipine on lipid peroxidation in patients with chronic heart failure].

Lipid peroxidation (LPO) was studied in 90 patients with chronic heart failure (CHF) in relation to the disease stage. The patients with various CHF showed increased LPO and decreased antioxidative function. Impaired LPO was more pronounced in patients with Stage II CHF. To correct LPO processes, emoxipine, a new synthetic antioxidant, was used in 48 patients. The agent in a dose of 40 mg/day was ascertained to have a regulatory effect on the oxidative-antioxidative system in patients with heart failure. A more profound effect was observed in patients with Stage I patients. The main mechanism of the antioxidative action of emoxipine in CHF was to enhance glutathione reductase and glutathione peroxidase and to lower the level on dienic conjugates in patients with Stage IIB CHF.

Adult↗
PubMed1988

[Change in lipid peroxidation in patients with primary osteoarthrosis deformans].

The content of blood lipid peroxidation products was studied in 62 patients with primary degenerative osteoarthrosis. High concentrations of malonic dialdehyde and acylhydroperoxide were revealed in multiple involvement of the joints, in the presence of reactive synovitis, and at the initial stage of disease. Enhanced lipid peroxidation reflected antioxidant deficiency. Antioxidants were recommended for the correction of disturbed lipid peroxidation in degenerative osteoarthrosis. Vitamin E (antioxidant of direct action) at a dose of 100 mg/day as part of multimodality therapy caused a decrease in the blood level of primary and secondary products of lipid peroxidation. Vitamin E was indicated in multiple involvement of the joints and reactive synovitis at the initial stage of degenerative osteoarthrosis.

Humans↗